What Ergamisol Treats: Main Uses and Benefits

Easing Periods of Heightened Symptomatic Discomfort

Levamisole (Ergamisol) is commonly used to help manage symptoms that may become intense or disruptive, such as those related to physical discomfort or systemic imbalance. It provides support that helps ease the overall symptom burden in situations involving certain distressing symptoms. The medicine is applied across therapeutic domains and is relevant in contexts involving heightened systemic burden.

It is considered relevant in conditions characterized by periods of heightened symptoms, like those involving episodic or fluctuating manifestations, and is applied during phases of increased distress or discomfort. This is relevant when symptoms become temporarily overwhelming, and the drug may assist with maintaining functional stability. When symptoms intensify and supportive relief is needed, Ergamisol is applied in addressing situations where symptoms create noticeable functional strain. It contributes to easing the overall symptom load and may help patients cope more steadily with symptom fluctuations.

---

Quick Fact: Supports Management of Symptoms that Interfere with Daily Functioning

---

Who Can and Cannot Use Ergamisol?

The population eligibility for Ergamisol (Levamisole Hydrochloride) is strictly governed by regulatory documentation, establishing specific groups for whom use is prohibited, restricted, or allowed.

Contraindicated Populations

The medicine is formally contraindicated and must not be used by any patient with a known hypersensitivity to Levamisole or its components, or with any pre-existing blood disorder. Regulatory labels also prohibit use if a patient has received or will receive organophosphorus compounds within 14 days of administration.

Conditional and Age-Related Use

Use is established in adult and pediatric populations for the approved anthelmintic indications in authorized regions. However, eligibility is restricted and requires special caution for patients with liver diseases, hepatic impairment, severe kidney diseases, Epilepsy, Rheumatoid Arthritis, or Sjögren Syndrome.

Reproductive Status Restrictions

The medicine is generally not recommended or contraindicated during pregnancy (often listed as FDA Category C) and is not recommended during lactation, based on World Health Organization guidance and international labeling. These restrictions reflect the official assessment of population-specific risk.

Interactions with other medicines and products

Interaction Scope

Detail	Official Regulatory Information
Medicinal product categories with documented interactions	Substrates of CYP2A6 and CYP2D6; Coumarin-derived anticoagulants; Organophosphorus compounds.
Specific interacting medicines (if explicitly listed)	Pimozide; Thioridazine; Phenytoin; Warfarin; Alcohol (Ethanol).
Mechanistic basis of interactions (only if stated in label)	Pharmacokinetic: Levamisole is a documented inhibitor of the CYP2A6 and CYP2D6 hepatic metabolic enzymes. Pharmacodynamic: Combination with alcohol leads to an Antabuse-like reaction.
Timing-based interaction rules (if applicable)	Treatment with Organophosphorus compounds requires a mandatory separation period of at least 14 days (before or after Levamisole treatment), as specified in some official regulatory documents.
Population-specific interaction notes (if applicable)	The significance of metabolic interactions may be heightened in patients with impaired hepatic function.
Interaction-related restrictions	Co-administration is formally prohibited with Pimozide and Thioridazine. Mandatory avoidance of alcohol (ethanol).

---

Interaction Classifications (High-Level)

Classification	Official Regulatory Information
Interaction severity classification	Contraindicated Combination (Pimozide, Thioridazine); Clinically Significant Interaction (Phenytoin, Warfarin, Alcohol); Restriction Required (Organophosphorus Compounds).
Interaction-context constraints	Interactions often result in increased plasma concentration of the co-administered drug.

Resulting Interaction Structure

Official interaction statements:

• Pimozide and Thioridazine are officially classified as contraindicated for co-administration due to the risk of increased plasma concentrations leading to potential cardiac risk.
• Levamisole's metabolic inhibition of CYP2A6 and CYP2D6 enzymes is the stated pharmacokinetic basis for the increased exposure of co-administered substrates.
• Co-administration with Phenytoin is documented to cause increased plasma concentrations.
• A formal pharmacodynamic intolerance reaction with alcohol (ethanol) may manifest as an Antabuse-like syndrome.
• The use of Levamisole may enhance the effect of coumarin-derived anticoagulants such as Warfarin.

Connection to the overall interaction profile:

Regulatory documents define the product’s interaction structure primarily through its capacity to inhibit hepatic metabolic enzymes, which results in elevated systemic exposure for numerous co-administered drugs. This effect establishes certain combinations, such as Pimozide, as formally contraindicated and requires restrictions for other substrates like Phenytoin and Warfarin.

How Ergamisol Works

Ergamisol (levamisole) acts through two primary, distinct pharmacodynamic mechanisms, resulting in specific physiological effects across different biological systems.

The first mechanism involves immunomodulation. The molecule affects specific transmitters and mediators within the immune system, primarily by directly stimulating the proliferation and activation of T-lymphocytes and enhancing the phagocytic activity of macrophages. Furthermore, it increases the production of various cytokines, thereby altering signaling patterns and enhancing cellular activity within immune pathways.

The second mechanism involves its action as a selective nicotinic acetylcholine receptor (nAChR) agonist. It targets the muscle cells of susceptible parasitic organisms, specifically nematodes. Binding to these post-synaptic receptors initiates a continuous, unregulated depolarization that causes sustained muscle contraction. This results in the complete and subsequent spastic paralysis of the parasite, a process that facilitates its clearance from the host's system.

How to Use Ergamisol

The usage of Levamisole (Ergamisol) follows specific routes, dosing, and scheduling, which vary based on the intended purpose. The medicine is primarily available in tablets and is intended for oral administration.

---

Dosing Regimens and Frequency

Specific patterns of use govern how often and for how long the medicine is administered:

Usage Pattern	Standard Adult Dosing	Frequency and Duration
Anthelmintic Use	150 mg (for parasitic infections)	Administered as a single oral dose.
Adjuvant Therapy	50 mg (three times daily)	Taken for 3 consecutive days, with this cycle repeated every two weeks for a period of up to one year.

---

Administration Context and Constraints

Specific conditions apply for proper intake and schedule management. Levamisole may be taken with or without food. For pediatric patients, the dose is calculated based on body weight, commonly 2.5 mg per kilogram as a single dose for anthelmintic use. A core procedural constraint for maintaining the therapeutic schedule is the instruction to skip a missed dose rather than doubling the subsequent dose. The two distinct dosing patterns—single acute use versus long-term intermittent cycles—establish the usage protocol for Ergamisol.

Research Evidence / Overview of Studies for Ergamisol

Evidence from Randomized Trials in Adjuvant Cancer Therapy

The research landscape for Levamisole includes large-scale Randomized Controlled Trials (RCTs) conducted on adults with Stage III colon cancer (Dukes' C). Researchers studied the use of Levamisole in combination with the chemotherapy agent fluorouracil, comparing this regimen to control groups. These studies focused on long-term outcomes, providing measurements of Overall Survival (OS) and Disease-Free Survival (DFS) over periods like five years. This research contributed to the evaluation of this two-drug combination in historical clinical practice. The relevance of the regimen to current practice is uncertain, as newer protocols have largely replaced this historical standard.

---

Studies for Preventing Relapse in Steroid-Sensitive Nephrotic Syndrome (SSINS)

Levamisole was studied for use in children with frequently relapsing SSINS. The research included controlled trials, such as double-blind, placebo-controlled designs, where Levamisole was studied as an adjuvant therapy. The trials monitored intermediate-term outcomes over periods of six months to a year, focusing on the frequency of relapse. Studies reported patterns of measured outcomes related to relapse-free intervals when comparing the study group to control groups. Long-term effects are not fully established, as follow-up durations were typically limited to one or two years.

---

Research in Parasitic Worm Infections

The primary research examined Levamisole in studies against common parasitic worm infections like Ascaris lumbricoides. These studies included adults and children and typically used short observation periods to monitor outcomes related to parasite clearance and reduction in worm burden. Research describes that the drug was observed in clinical settings during studies examining short-term clearance of parasites. Comparative evidence is lacking for some of the less common parasitic species, and data are still emerging regarding its performance against emerging drug resistance patterns.

---

Long-Term Outcomes and Research Gaps

Evidence for the use in colon cancer examined long-term survival, but studies for nephrotic syndrome primarily provide data for intermediate follow-up durations. High-quality data for special groups, such as older adults, remain insufficient. The scientific literature also notes inconsistency in research exploring the drug's role as an immunomodulator, and the relationship between this function and different studied conditions is not fully established.

Common questions about Ergamisol (FAQ)

Q: Why is Ergamisol sometimes mentioned in relation to both parasitic infections and cancer?

A: Official information indicates that Ergamisol (levamisole) has a two-fold classification as both an anthelmintic (a drug used against parasitic worms) and as an immunomodulator (a substance that helps regulate the immune system). This dual function led to its historical study and limited use for both parasitic infections and as adjuvant therapy (additional treatment) for certain cancers.

Q: Is a rash a common reaction to taking Ergamisol?

A: Regulatory documents indicate that a rash is a documented adverse reaction to Ergamisol. In clinical data, a rash was reported as a common side effect. More severe skin reactions resulting from vasculitis (blood vessel inflammation) are also possible, according to official warnings.

Q: Can Ergamisol cause changes in blood cell counts?

A: Yes, official warnings highlight that this medication is associated with hematologic toxicity, meaning it can affect blood cell production. This primarily involves a potentially severe decrease in white blood cells, referred to as agranulocytosis or leukopenia. Due to this risk, close monitoring by a healthcare professional, including frequent blood tests, is often required during treatment.

Q: What kind of blood tests are typically done when a person is taking Ergamisol?

A: Due to the risk of hematologic toxicity, official product information states that frequent blood count checks are required while a person is taking this medication. These tests monitor for changes in blood cell levels, such as drops in white blood cell counts (leukopenia or agranulocytosis), as required by regulatory documentation.

Q: Can Ergamisol interact with other prescription medications, like blood thinners or diabetes drugs?

A: Yes, regulatory documents confirm that Ergamisol can interact with many other prescription medications. For example, it can interact with blood thinners like Warfarin, potentially enhancing their effect. The basis for many interactions is that it inhibits certain liver enzymes (CYP2A6 and CYP2D6), which may cause the concentration of other co-administered drugs to increase.

Q: Does Ergamisol affect fertility in men or women?

A: Regulatory safety data focuses primarily on the need for avoidance during pregnancy and lactation. Some official data suggests Levamisole may cause damage to organs such as the testis with prolonged exposure. It is also classified as being suspected of damaging the unborn child.

Q: Does Ergamisol cause tiredness or dizziness?

A: According to regulatory adverse reaction sections, fatigue (tiredness) and dizziness are documented as common central nervous system or systemic side effects of Ergamisol.

Q: Can taking Ergamisol affect your sense of taste or smell?

A: Official product information notes that Ergamisol is associated with sensory side effects. It is known to cause a metallic taste in the mouth and can also cause a change in your sense of taste and smell.

Q: What is the risk of agranulocytosis associated with Ergamisol?

A: Agranulocytosis is a drastic, serious drop in white blood cells that is a major safety concern with Ergamisol. Historical reports cited in regulatory data indicate a varied range of incidence, with some studies reporting this risk in up to 13% of patients who were on the prolonged, high-dosage regimen.

Q: Should I avoid certain foods or drinks while taking Ergamisol?

A: The official labeling mandates the avoidance of alcohol (ethanol) while taking this medication. Co-administration can lead to a severe intolerance reaction known as an Antabuse-like syndrome.

Q: Is Ergamisol safe for children?

A: Official information confirms that Ergamisol has established use for its approved anthelmintic (anti-worm) indications in pediatric populations in certain regions. However, for some other historical indications, its use is generally not recommended for children.

Q: Does Ergamisol cause any central nervous system side effects like confusion or memory issues?

A: Yes, official labeling lists several potential Central Nervous System abnormalities. These include common side effects like dizziness and the inability to concentrate, as well as more serious and rare issues like confusion and a specific type of brain disease (encephalopathy-like syndrome) which can involve memory loss.

Q: Is Ergamisol still available or commonly used in the United States?

A: Regulatory documents reflect that the drug was withdrawn from the US market in the early 2000s due to significant safety concerns, particularly the risk of agranulocytosis. It may, however, remain available and used in other countries globally, primarily as an anthelmintic.

Q: Is Ergamisol included on the World Health Organization's List of Essential Medicines?

A: Yes, Levamisole (Ergamisol) is included on the World Health Organization’s Model List of Essential Medicines (EML). It is listed specifically for its use as an intestinal anthelminthic (anti-worm medication).

How to Store and Dispose of Ergamisol (Levamisole)

Storage Requirements

Ergamisol must be stored at room temperature, typically 15-25 °C (59-77 °F), and kept from freezing. The medicine must be protected from direct light, heat, and moisture to maintain its stability. Store the product in its container, ensuring it remains tightly closed.

Child-Safety Storage

It is mandatory to store the medicine locked up (P405) and out of the reach of children to prevent unauthorized access.

Disposal Instructions

Expired or unused Ergamisol must be disposed of according to local, regional, and national regulations (P501). Disposal must avoid release to the environment, meaning the product should not be discharged into sewer systems, drains, or soil.